Emyria

D4, 661 Newcastle Street
Leederville WA 6007

Home

Contact Us

Updates

Corporate Governance

Annual Reports

Share Price

Announcements

New investors

Why Invest in Emyria?

Investor Research

Loyalty Option Offer

Presentations

Successes

Meet the Team

About Emyria

Webinars

Montserrat

Emyria Limited

Psychedelics as a serious investment? These billionaires think so

upload.jpg

The Food and Drug Administration (FDA) in the United States is calling for more data before approving MDMA for the treatment of post-traumatic stress disorder (PTSD).  – this is not a vote against MDMA, it is a call for more robust data. A critical distinction to make.

With no new PTSD drugs approved in over 20 years, this decision simply underscores the urgent need for thorough, follow-up research.

Emyria’s proven success in delivering medication-assisted therapies under Australia’s rigorous regulatory framework demonstrates our unique readiness. Today, the Company was highlighted in a full-page feature in the Australian Financial Review by Health Editor Michael Smith titled “Psychedelics as a serious investment? These billionaires think so”.

The story explores, in detail, the investment opportunity and clinical impact of key players who are pioneering novel treatments for mental health conditions – including commentary from Emyria CEO and MD, Dr Michael Winlo.

By operating in Australia, a jurisdiction where this therapy is legally allowed, Emyria already has a distinct global advantage, and now a profound opportunity, to positively impact patient lives and gather the robust data required to advance this field.

AFR Feature Story